Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Madrigal Pharmaceuticals Inc (NQ: MDGL ) 256.17 -3.00 (-1.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Madrigal Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > Madrigal Pharmaceuticals Stock Shows Rising Relative Strength February 06, 2024 A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. Via Investor's Business Daily 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 06, 2024 Via Benzinga 2 Rising Biotechs That Could Become the Next Novo Nordisk January 29, 2024 Each of these companies has a big market in its sights. Via The Motley Fool 2 Stocks That Could Soar This Year: Are They Buys? January 22, 2024 They might perform well in 2024, but how will they do beyond that? Via The Motley Fool Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development January 12, 2024 89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. Via Benzinga Analyst Ratings for Madrigal Pharmaceuticals November 13, 2023 Via Benzinga 2 Risky Stocks With Massive Potential October 17, 2023 Neither is doing well this year. Via The Motley Fool 1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street September 20, 2023 This company is on the brink of a major breakthrough. Via The Motley Fool Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Leading Gainer in 9/13 Morning Trading September 13, 2023 Via Investor Brand Network 3 Stocks That Could Be Monster Winners in 2024 December 30, 2023 Don't be surprised if these three stocks take off in the new year. Via The Motley Fool Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session December 08, 2023 Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. Via Benzinga These 2 Stocks Could Be About to Soar: Are They Buys? December 07, 2023 One thing is for certain -- both of these companies are innovators. Via The Motley Fool Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money November 30, 2023 These stocks just might have investors seeing double over the next few years. Via The Motley Fool The Latest Analyst Ratings for Madrigal Pharmaceuticals September 11, 2023 Via Benzinga Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? November 21, 2023 New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... Via Benzinga Topics ETFs Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating November 17, 2023 Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. Via Investor's Business Daily The 3 Most Undervalued Biotech Stocks to Buy: November 2023 November 14, 2023 Given the undervalued biotech industry, these three undervalued biotech stocks to buy are ripe purchase targets for high-potential profits. Via InvestorPlace 10 Health Care Stocks Whale Activity In Today's Session November 02, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session October 19, 2023 Via Benzinga Nike, Carnival And 3 Stocks To Watch Heading Into Friday September 29, 2023 With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Via Benzinga Nike, Carnival, Activision Blizzard, Madrigal Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today? September 28, 2023 U.S. stocks traded higher with the Dow Jones gaining over 110 points on Thursday. The Dow traded up 0.35% to 33,666.34 while the NASDAQ rose 0.83% to 13,201.28. Via Benzinga Topics Stocks Exposures US Equities Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon. September 27, 2023 It has a good shot at commercializing a drug to treat a common liver disease. Via The Motley Fool Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease September 21, 2023 Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... Via Benzinga Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line September 13, 2023 The company is toeing the finish line with a NASH treatment, an area of medicine marked by failures. Via Investor's Business Daily Smucker, FuelCell Energy, Granite Ridge Resources And Other Big Stocks Moving Lower On Monday September 11, 2023 U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording losses in today’s session. IHS Holding Limited (NYSE: IHS) shares fell 15.7% to... Via Benzinga Topics Stocks Exposures US Equities The 3 Best Biotech Stocks to Buy Now: September 2023 September 04, 2023 With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. Via InvestorPlace 3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of August 30, 2023 Worries about biotech stocks are way overdone, so the sector should make a big comeback in the coming months. Via InvestorPlace The 3 Most Promising Pharma Stocks to Own Now August 30, 2023 A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. Via InvestorPlace 3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? August 23, 2023 NASH treatments are projected to be one of the most sought-after indications in the coming years. Via The Motley Fool Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It August 23, 2023 NASH is a surprisingly common ailment, and the first treatments are on the way. Via The Motley Fool < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.